Similarly, this would also suggest that in addition to screening of patients for KRAS mutation status, stratification of patients with KRAS allelic status that corresponds to selective pressure for outgrowth of tumours with increased MAPK signalling are more likely to render this subset of patients more susceptible to effector pathway inhibitors. The gene discussed is KRAS; the disease is neoplasm.